AUA Foundation names new director of research
Leo Giambarresi, PhD, has joined the AUA Foundation as the director of research. Dr. Giambarresi is currently the prostate cancer research program manager at the Battelle Memorial Institute, U.S. Army Medical Research and Material Command, Fort Detrick, MD, where he leads a multidisciplinary team of government and contract scientists, clinicians, consumers, and support staff to execute all aspects of an $80 million appropriations budget for prostate cancer research.
Leo Giambarresi, PhD, has joined the AUA Foundation as the director of research. Dr. Giambarresi is currently the prostate cancer research program manager at the Battelle Memorial Institute, U.S. Army Medical Research and Material Command, Fort Detrick, MD, where he leads a multidisciplinary team of government and contract scientists, clinicians, consumers, and support staff to execute all aspects of an $80 million appropriations budget for prostate cancer research.
Dr. Giambarresi earned his bachelor of science in biochemistry from the University of Massachusetts and his PhD in experimental pathology from the University of Pittsburgh.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
